Compare NXTC & MXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXTC | MXC |
|---|---|---|
| Founded | 2015 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 17.6M |
| IPO Year | 2019 | 1995 |
| Metric | NXTC | MXC |
|---|---|---|
| Price | $7.98 | $10.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 192.3K | 56.2K |
| Earning Date | 05-04-2026 | 02-10-2026 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.24 |
| Revenue | ★ $22,378,000.00 | $2,705,235.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $45.92 |
| Revenue Growth | N/A | ★ 7.12 |
| 52 Week Low | $1.55 | $7.16 |
| 52 Week High | $15.74 | $16.48 |
| Indicator | NXTC | MXC |
|---|---|---|
| Relative Strength Index (RSI) | 66.07 | 64.59 |
| Support Level | $3.98 | $8.66 |
| Resistance Level | $8.72 | $10.80 |
| Average True Range (ATR) | 0.73 | 0.70 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 85.56 | 95.87 |
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Mexco Energy Corporation is an independent oil and gas company. It is engaged in the acquisition, exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.